SMAD6 contributes to patient survival in non-small cell lung cancer and its knockdown reestablishes TGF-beta homeostasis in lung cancer cells.

The malignant transformation in several types of cancer, including lung cancer, results in a loss of growth inhibition by transforming growth factor-beta (TGF-beta). Here, we show that SMAD6 expression is associated with a reduced survival in lung cancer patients. Short hairpin RNA (shRNA)-mediated knockdown of SMAD6 in lung cancer cell lines resulted in reduced cell viability and increased apoptosis as well as inhibition of cell cycle progression. However, these results were not seen in Beas2B, a normal bronchial epithelial cell line. To better understand the mechanism underlying the association of SMAD6 with poor patient survival, we used a lentivirus construct carrying shRNA for SMAD6 to knock down expression of the targeted gene. Through gene expression analysis, we observed that knockdown of SMAD6 led to the activation of TGF-beta signaling through up-regulation of plasminogen activator inhibitor-1 and phosphorylation of SMAD2/3. Furthermore, SMAD6 knockdown activated the c-Jun NH2-terminal kinase pathway and reduced phosphorylation of Rb-1, resulting in increased G0-G1 cell arrest and apoptosis in the lung cancer cell line H1299. These results jointly suggest that SMAD6 plays a critical role in supporting lung cancer cell growth and survival. Targeted inactivation of SMAD6 may provide a novel therapeutic strategy for lung cancers expressing this gene.

[1]  M. Reiss,et al.  A mutation in the transforming growth factor beta type II receptor gene promoter associated with loss of gene expression. , 1996, Cancer research.

[2]  C. Heldin,et al.  Identification of Smad7, a TGFβ-inducible antagonist of TGF-β signalling , 1997, Nature.

[3]  K. Miyazono,et al.  Divergence and convergence of TGF‐β/BMP signaling , 2001, Journal of cellular physiology.

[4]  T. Waldman,et al.  Suppression of tumorigenesis and activation of Wnt signaling by bone morphogenetic protein 4 in human cancer cells , 2004, Cancer biology & therapy.

[5]  H. Friess,et al.  The TGF-β signaling inhibitor Smad7 enhances tumorigenicity in pancreatic cancer , 1999, Oncogene.

[6]  S. Park,et al.  Smad6 negatively regulates interleukin 1-receptor–Toll-like receptor signaling through direct interaction with the adaptor Pellino-1 , 2006, Nature Immunology.

[7]  Jennifer Lee,et al.  Smad7 but not Smad6 cooperates with oncogenic ras to cause malignant conversion in a mouse model for squamous cell carcinoma. , 2003, Cancer research.

[8]  R. Weinberg,et al.  Transforming growth factor beta-induced phosphorylation of Smad3 is required for growth inhibition and transcriptional induction in epithelial cells. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[9]  Takeo Iwama,et al.  Higher frequency of Smad4 gene mutation in human colorectal cancer with distant metastasis , 1999, Oncogene.

[10]  Kohei Miyazono,et al.  TGF-β signalling from cell membrane to nucleus through SMAD proteins , 1997, Nature.

[11]  Denis Vivien,et al.  Direct binding of Smad3 and Smad4 to critical TGFβ‐inducible elements in the promoter of human plasminogen activator inhibitor‐type 1 gene , 1998, The EMBO journal.

[12]  Xin-Hua Feng,et al.  Smad6 Recruits Transcription Corepressor CtBP To Repress Bone Morphogenetic Protein-Induced Transcription , 2003, Molecular and Cellular Biology.

[13]  R. Derynck,et al.  TGF-beta signaling in cancer--a double-edged sword. , 2001, Trends in cell biology.

[14]  K. Miyazono,et al.  Smad6 inhibits signalling by the TGF-β superfamily , 1997, Nature.

[15]  J. Massagué,et al.  Smad6 inhibits BMP/Smad1 signaling by specifically competing with the Smad4 tumor suppressor. , 1998, Genes & development.

[16]  R. Davis,et al.  Evidence for a Role of Rho-like GTPases and Stress-activated Protein Kinase/c-Jun N-terminal Kinase (SAPK/JNK) in Transforming Growth Factor β-mediated Signaling* , 1997, The Journal of Biological Chemistry.

[17]  J. Harbour,et al.  Rb function in cell-cycle regulation and apoptosis , 2000, Nature Cell Biology.

[18]  H. Kuwano,et al.  Prognostic value of the expression of Smad6 and Smad7, as inhibitory Smads of the TGF-beta superfamily, in esophageal squamous cell carcinoma. , 2004, Anticancer research.

[19]  R. Derynck,et al.  TGF-β signaling in cancer – a double-edged sword , 2001 .

[20]  J. Wrana,et al.  The MAD-Related Protein Smad7 Associates with the TGFβ Receptor and Functions as an Antagonist of TGFβ Signaling , 1997, Cell.

[21]  R. Weinberg,et al.  Absence of TGF-beta receptors and growth inhibitory responses in retinoblastoma cells. , 1988, Science.

[22]  Y. Yatabe,et al.  Induction of apoptosis by Smad3 and down-regulation of Smad3 expression in response to TGF-β in human normal lung epithelial cells , 1998, Oncogene.

[23]  J. Massagué,et al.  TGF- SIGNAL TRANSDUCTION , 1998 .

[24]  Ester Piek,et al.  Role of Transforming Growth Factor-β Signaling in Cancer , 2000 .

[25]  M. Sporn,et al.  Type beta transforming growth factor is the primary differentiation-inducing serum factor for normal human bronchial epithelial cells. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[26]  R. Weiss,et al.  Smad6 Represses Dlx3 Transcriptional Activity through Inhibition of DNA Binding* , 2006, Journal of Biological Chemistry.

[27]  A. Näär,et al.  A component of the ARC/Mediator complex required for TGFβ/Nodal signalling , 2002, Nature.

[28]  M. Laiho,et al.  Transforming growth factor‐beta is a strong and fast acting positive regulator of the level of type‐1 plasminogen activator inhibitor mRNA in WI‐38 human lung fibroblasts. , 1987, The EMBO journal.

[29]  K. Mohammad,et al.  Stable overexpression of Smad7 in human melanoma cells impairs bone metastasis. , 2007, Cancer research.

[30]  K. Miyazono,et al.  Effect of Smad7 expression on metastasis of mouse mammary carcinoma JygMC(A) cells. , 2005, Journal of the National Cancer Institute.

[31]  H. Lodish,et al.  Role of transforming growth factor beta in human disease. , 2000, The New England journal of medicine.

[32]  Y. Bang,et al.  Transcriptional repression of the transforming growth factor-β type I receptor gene by DNA methylation results in the development of TGF-β resistance in human gastric cancer , 1999, Oncogene.

[33]  R. Davis,et al.  Signal Transduction by the JNK Group of MAP Kinases , 2000, Cell.

[34]  J. Massagué.  TGF-beta signal transduction. , 1998, Annual review of biochemistry.

[35]  C. Osborne,et al.  Transforming growth factor β: potential autocrine growth inhibitor of estrogen receptor-negative human breast cancer cells , 1988 .

[36]  Ravi Kiran Reddy Kalathur,et al.  Expression profiling of genes regulated by TGF-beta: Differential regulation in normal and tumour cells , 2007, BMC Genomics.

[37]  M. Washington,et al.  Plasma transforming growth factor-beta 1 reflects disease status in patients with lung cancer after radiotherapy: a possible tumor marker. , 1996, Lung cancer.

[38]  L. Attisano,et al.  Mutations in the tumor suppressors Smad2 and Smad4 inactivate transforming growth factor beta signaling by targeting Smads to the ubiquitin-proteasome pathway. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[39]  K. Miyazono,et al.  The N domain of Smad7 is essential for specific inhibition of transforming growth factor-β signaling , 2001, The Journal of cell biology.

[40]  福岡 順也.  Chromatin remodeling factors and BRM/BRG1 expression as prognostic indicators in non-small cell lung cancer , 2004 .